Drug Profile
MIQ 001
Alternative Names: MIQ-001Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator Meta-IQ
- Class Small molecules
- Mechanism of Action Carnitine O-palmitoyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis; Optic neuritis
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Multiple-sclerosis in Denmark
- 28 Apr 2019 No recent reports of development identified for phase-I development in Optic-neuritis in Denmark
- 30 Mar 2016 Phase-I clinical trials in Multiple sclerosis in Denmark (unspecified route)